Cogstate Adds Veteran ASX CFO Darryl Inns to Board in Governance Refresh

An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.

Cogstate Ltd, a specialist in CNS clinical trial endpoint data quality and digital cognitive assessments, has strengthened its board with the appointment of former ASX-listed company CFO Darryl Inns as a Non-Executive Director, effective 1 May 2026. Inns brings more than 30 years of finance and executive leadership experience, including two decades at ASX200 companies and a track record in driving growth, complex M&A and capital management.

The appointment forms part of Cogstate’s ongoing board renewal and succession program, following the 2025 departure of director Richard van den Broek, and will see Inns join the Audit, Risk & Compliance and Nomination Committees. The company has also reconfigured its board committees to enhance independence and governance, with Chair Martyn Myer stepping down from the Audit, Risk & Compliance and Remuneration Committees while independent directors Ingrid Player and Kim Wenn continue to lead those bodies.

The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.

More about Cogstate Ltd

Cogstate Ltd is a global Central Nervous System endpoint innovations company that partners with pharmaceutical and biotech drug developers to support complex neuroscience studies. The company provides digital cognitive testing, data quality programs and advanced analytics to deliver accurate, actionable clinical trial endpoint data, and also targets the healthcare market with brief, self-administered cognitive assessments for primary care use.

Average Trading Volume: 197,268

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$417.2M

For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.